Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice
- 1 June 2002
- journal article
- Published by Elsevier in Brain Research
- Vol. 942 (1-2), 23-30
- https://doi.org/10.1016/s0006-8993(02)02649-5
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Mevastatin, an HMG-CoA Reductase Inhibitor, Reduces Stroke Damage and Upregulates Endothelial Nitric Oxide Synthase in MiceStroke, 2001
- Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca.The American Journal of Cardiology, 2001
- Atorvastatin Upregulates Type III Nitric Oxide Synthase in Thrombocytes, Decreases Platelet Activation, and Protects From Cerebral Ischemia in Normocholesterolemic MiceStroke, 2000
- Uptake of HMG-CoA reductase inhibitor ZD4522 into hepatocytes and distribution into liver and other tissues of the ratAtherosclerosis, 2000
- Neuroprotection mediated by changes in the endothelial actin cytoskeletonJournal of Clinical Investigation, 2000
- Endothelial Nitric Oxide Synthase-Dependent Cerebral Blood Flow Augmentation by L-Arginine After Chronic Statin TreatmentJournal of Cerebral Blood Flow & Metabolism, 2000
- Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.Journal of Clinical Investigation, 1998
- AtorvastatinDrugs, 1997
- Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme a reductaseThe American Journal of Cardiology, 1994
- Regulation of the mevalonate pathwayNature, 1990